Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
An article from
Dive Brief
Mixed Phase 3 data for camlipixant prompted the British pharma to cease development, making the drug the third from its class to fail.
Published July 17, 2026
A GSK logo is seen on the side of an office building in Poznan, Poland.
Disappointing Data Prompts GSK to Drop Cough Drug Development - GSK (NYSE:GSK)
Pharma: GSK stellt Forschung an Hustenmedikament ein
What's Going on With GSK Stock Monday? - GSK (NYSE:GSK)
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win
GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testing it for irritable bowel…
GSK PLc beendet nach gemischten Studienergebnissen die Entwicklung des Medikamentes Camlipixant gegen chronischen Husten. Anleger…
Clinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline…
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy. |…
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
